East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Betamethasone Dipropionate Ointment USP, (Augmented), 0.05%. Aurobindo Pharma’s Betamethasone Dipropionate Ointment, are an AB-rated generic equivalent to the reference listed drug (RLD), Diprolene® Ointment manufactured by Organon LLC.

Betamethasone Dipropionate Ointment are indicated for:

• The relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.